{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:33:53Z","timestamp":1764174833299,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.urolonc.2020.07.012","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T16:40:15Z","timestamp":1596904815000},"page":"793.e1-793.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry"],"prefix":"10.1016","volume":"38","author":[{"given":"Hala T.","family":"Borno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet E.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoujun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette M.","family":"Broering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2020.07.012_bib0001","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0002","unstructured":"2020 [cited 2020 Feb 27]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed Feb 27, 2020."},{"key":"10.1016\/j.urolonc.2020.07.012_bib0003","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0004","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","article-title":"Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States","volume":"4","author":"Kelly","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0005","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0006","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","article-title":"Effect of orchiectomy and irradiation on cancer of the prostate","volume":"115","author":"Huggins","year":"1942","journal-title":"Ann Surg"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0008","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.eururo.2014.08.076","article-title":"Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the prostate cancer consortium in Europe","volume":"67","author":"Fizazi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0009","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MOU.0000000000000444","article-title":"Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?","volume":"27","author":"Blanchard","year":"2017","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11864-016-0439-8","article-title":"Oligometastatic prostate cancer","volume":"17","author":"Stevens","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0011","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0012","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0090-4295(96)00226-9","article-title":"The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE research panel. Cancer of the prostate strategic urologic research endeavor","volume":"48","author":"Lubeck","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0013","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00345-011-0658-3","article-title":"The example of CaPSURE: lessons learned from a national disease registry","volume":"29","author":"Porten","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0014","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrurol.2017.72","article-title":"Prostate cancer: 'The prostate' in patients with metastatic prostate cancer: to treat or not to treat?","volume":"14","author":"Saad","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","article-title":"Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial","volume":"103","author":"James","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2017.06.007","article-title":"Redefining hormonal therapy for advanced prostate cancer: results from the LATITUDE and STAMPEDE Studies","volume":"32","author":"Small","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0017","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrurol.2017.115","article-title":"Prostate cancer: STAMPEDE, LATITUDE and Fernand Labrie's legacy","volume":"14","author":"Tombal","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0018","doi-asserted-by":"crossref","first-page":"315","DOI":"10.21037\/tau.2017.02.01","article-title":"Treatment of metastatic prostate cancer after STAMPEDE","volume":"6","author":"Wolf","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.critrevonc.2016.08.007","article-title":"Prostate cancer perspectives after chaarted: optimizing treatment sequence","volume":"107","author":"Estevez","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000447341","article-title":"The STAMPEDE trial","volume":"39","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/2159-8290.CD-17-0481","article-title":"The path of most resistance: transdifferentiation underlies exceptional nonresponses to androgen receptor pathway inhibition in prostate cancer","volume":"7","author":"Sinha","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urolonc.2008.03.021","article-title":"Mechanisms mediating androgen receptor reactivation after castration","volume":"27","author":"Yuan","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2020.07.012_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.22736","article-title":"Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE","volume":"110","author":"Ryan","year":"2007","journal-title":"Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030332X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392030332X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:39Z","timestamp":1761041919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392030332X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S107814392030332X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}